Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
Caitlin Costello, MD, describes how to determine if a patient with MM is transplant-ineligible, and some factors to take into consideration when choosing a treatment regimen.
EP: 1.Choosing the Appropriate Induction Regimen in Transplant-Eligible NDMM
EP: 2.Minimal Residual Disease-Response Adapted Therapy in Transplant-Eligible NDMM
EP: 3.Determining the Right Patients with NDMM for Autologous Stem Cell Transplant
EP: 4.Duration of Therapy and Maintenance Treatment in Transplant-Eligible NDMM
EP: 5.Treating Patients with High-Risk NDMM
Now Viewing
EP: 6.Factors to Consider for Frontline Treatment of Transplant-Ineligible MM
EP: 7.Transplant-Ineligible Multiple Myeloma: The MAIA and SWOG 0777 Trials
EP: 8.Transplant-Ineligible Multiple Myeloma: The ENDURANCE Study
EP: 9.Role of Triplet Therapy in Frail Patients with Transplant-Ineligible NDMM
EP: 10.Maintenance Therapy in Transplant-Ineligible NDMM
EP: 11.Available Treatment Options for Relapsed/Refractory Multiple Myeloma
EP: 12.Bispecific Antibodies in the Treatment of R/R MM
EP: 13.CAR-T Therapy in R/R MM Treatment
EP: 14.Choosing a Bispecific Antibody for Treatment of R/R MM After Prior BCMA Therapy
EP: 15.Sequencing Therapies in Patients with R/R MM
EP: 16.Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022
EP: 17.Recap: Recent Advances in Multiple Myeloma From IMS 2022 and Beyond
Recent Videos
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
